Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies for autoimmune diseases. Its lead candidate, obexelimab—a bifunctional monoclonal antibody targeting CD19 and FcγRIIb—is in global Phase III trials for IgG4-related disease and Phase II trials for multiple sclerosis and systemic lupus erythematosus. The company has also entered into strategic licensing agreements with major pharmaceutical partners such as Bristol Myers Squibb to expand the reach of its therapies in Asia-Pacific markets[5][7].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zenova BioPharma.